. ● . Intelligent Bio Solutions to Present at the LD Micro Main Event XVII on October 28-30 in Los Angeles October 16, 2024 8:00 AM EDT | Source: LD Micro New York, New York--(Newsfile Corp. - October 16, 2024) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present in the upcoming LD Micro Main Event XVII on October 28-30, 2024, in Los Angeles. ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company's clinical study plan. The clinical studies are a key element of the Company's 510(k) submission, designed to demonstrate the accuracy and reliability of its sweat-based testing method. ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK's largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing. "We are thrilled to partner with Intelligent Fingerprinting to enhance our approach to workplace safety," said Emma Bullock, Head of Peopl ...

- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided ...

Company Overview - Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on innovative, rapid, non-invasive testing solutions [2] - The company’s Intelligent Fingerprinting Drug Screening System utilizes fingerprint sweat analysis, aiming to revolutionize portable testing with potential applications in various fields [2] - The system is designed to be hygienic and cost-effective, screening for recent drug use, including opiates, cocaine, methamphetamine, and cannabis [2] Technology and Applications - The testing process allows for sample collection in seconds and provides results in under ten minutes, making it a valuable tool for employers in safety-critical industries [2] - The company's biosensor platform has the potential to test for a range of indications, from immunological conditions to communicable diseases [2] Customer Segments - Current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners [2] Upcoming Events - The management team will participate in the Sidoti Small-Cap Virtual Conference on September 18-19, 2024, with a presentation scheduled for September 19 at 2:30 p.m. Eastern Time [1]

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its progress toward completion of the clinical study plan required for its FDA 510(k) submission. In August 2024, INBS announced its partnership with CenExel to perform the method comparison study as part of the Company's clinical study plan. The study involves the recruitment of 135 h ...

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced significant growth in its customer employee base, reporting a 118% fiscal year-over-year increase in the estimated total number of employees across its customer base. As of June 30, 2024, the estimated number of employees within INBS' global customer base has grown by 720,000 compared to an increase of 329,000 the fiscal year ...

Core Insights - Intelligent Bio Solutions Inc. (INBS) has achieved the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers, indicating a significant milestone and growing demand for its non-invasive drug testing technology [1][4] Sales Performance - In the fiscal year ending June 30, 2024, the company sold 407 readers, representing a 26% increase from 323 readers sold in the previous fiscal year [2] - The total number of installed readers reached 1,037 as of June 30, 2024, marking a 65% increase from 630 installed readers as of June 30, 2023 [2] Product Overview - The Intelligent Fingerprinting Drug Screening System includes a DSR-Plus portable analysis unit and tamper-proof cartridges, designed for quick and reliable drug detection using lateral flow assay technology [3] - Results from the system are available within 10 minutes, with a unique 16-hour detection window for drug use, making it suitable for workplace screening [3] Cartridge Sales and Revenue - The company experienced a 20% year-over-year increase in cartridge sales, rising from 67,575 cartridges in 2023 to 81,075 cartridges in 2024 [4] - Repeat sales of cartridges contribute to a robust and ongoing revenue stream for the company [4] Regulatory Progress - The company is making progress towards FDA clearance, with the FDA provisionally determining that the cartridges are a Class II type device requiring a pre-market notification 510(k) submission [4] Market Position and Future Outlook - Intelligent Bio Solutions is positioned for further expansion in both the United States and internationally, continuing to lead in non-invasive drug testing technology [4]

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as construction, manufacturing, transport and warehousing, mining, and automotive. As the need for robust drug testing solutions intensifies, we believe that our company is positioned to lead the way in providing innovative, non-invasive drug testing technologies. The challenges faced across these critical sectors are: ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel, a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company's FDA 510(k) clinical study plan. The Company's method comparison study will recruit 135 healthy adult subjects across three sites under an IRB- ...